secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001356576-23-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q2 total revenues down 20% to $135.5M; Qelbree sales up 179%
---------------------------------------------------------------------

- GAAP operating loss of $17.6M vs income of $11.3M in Q2 2022; net loss $0.8M ($0.02 loss per share).
- Qelbree net sales $31.0M (+179% YoY), GOCOVRI $28.8M (+17%); Trokendi XR fell 73% to $19.3M on generic erosion.
- Non-GAAP adjusted operating earnings of $10.0M in Q2 vs $37.6M a year ago; six-month adjusted earnings $40.5M.
- Full-year 2023 guidance reaffirmed: revenues $580–620M, GAAP operating loss ($30)–($10)M, non-GAAP op earnings $75–100M.
- Cash and marketable securities $189.1M at June 30; completed $402.5M convertible note and $93M credit line repayments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/supn-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer